Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exicorilant and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
NCT03437941Phase 2Terminated
- Sponsor
- Corcept Therapeutics
- Start
- Feb 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of exicorilant in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Corcept Therapeutics. Started Feb 2018; status: terminated.
02
Drugs
exicorilant
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03437941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437941.